Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Objective: Youth at clinical high risk (CHR) for psychosis often demonstrate significant negative symptoms, which have been reported to be predictive of conversion to psychosis and a reduced quality of life but treatment options for negative symptoms remain inadequate. Therefore, we conducted a systematic review and network meta-analysis of all intervention studies examining negative symptom outcomes in youth at CHR for psychosis. Method: The authors searched PsycINFO, Medline, Embase, CINAHL, and EBM from inception to December 2016. Studies were selected if they included any intervention that reported follow-up negative symptoms in youth at CHR for psychosis. Treatment comparisons were evaluated using both pairwise and network meta-analyses. Due to the differences in negative symptom scales the effect sizes were reported as the standardized mean difference (SMD). Results: Of 3027 citations, 32 studies met our inclusion criteria, including a total of 2463 CHR participants. The null hypothesis was not rejected for any of the 11 treatments. N-methyl-D-aspartate-receptor (NMDAR) modulators trended toward a significant reduction in negative symptoms compared to placebo (SMD = -0.54; 95% CI = -1.09 to 0.02; I2 = 0%, P = .06). In respective order of descending effectiveness as per the treatment hierarchy, NMDAR modulators were more effective than family therapy, need-based interventions, risperidone, amisulpride, cognitive behavioral therapy, omega-3, olanzapine, supportive therapy, and integrated psychological interventions. Conclusions: Efficacy and effectiveness were not confirmed for any negative symptom treatment. Many studies had small samples and the majority were not designed to target negative symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PRISMA-P Group, Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015) · Systematic Reviews · doi:10.1186/2046-4053-4-1 · Cited by 26,223
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
The role and interpretation of pilot studies in clinical research
Leon, A. C., Davis, L. L., & Kraemer, H. C. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.10.008 · Cited by 1,917
Puhan, M. A., Schunemann, H. J., Murad, M. H., Li, T., Brignardello-Petersen, R., Singh, J. A., Kessels, A. G., Guyatt, G. H., & for the GRADE Working Group (2014) · BMJ · doi:10.1136/bmj.g5630 · Cited by 1,812
Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1037 · Cited by 1,729
Meta-analysis of experiments with matched groups or repeated measures designs
Dunlap, W. P., Cortina, J. M., Vaslow, J. B., & Burke, M. J. (1996) · Psychological Methods · doi:10.1037/1082-989x.1.2.170 · Cited by 1,693
Simultaneous comparison of multiple treatments: Combining direct and indirect evidence.
Caldwell, D. M., Ades, A. E., & Higgins, J. P. T. (2005) · BMJ · doi:10.1136/bmj.331.7521.897 · Cited by 1,600
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483 · cited 2×
“The following clinical outcome data were extracted: (1) mean ± SD negative symptom scores at follow-up and baseline, (2) sample size per treatment group, and (3) paired pre/post negative symptom scores for nonrandomized controlled studies with the P or t value of change in negative symptom scores.”
MethodSelf-citation
Research works printed but not linked: 67
- McGlashan, 2010, The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-up
- Yung, 2005, Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States, Aust N Z J Psychiatry, 39, 964, 10.1080/j.1440-1614.2005.01714.x · DOI · Paper page
- Fusar-Poli, 2007, Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis, Med Hypotheses, 69, 959, 10.1016/j.mehy.2006.12.044 · DOI
- Lencz, 2004, Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia, Schizophr Res, 68, 37, 10.1016/S0920-9964(03)00214-7 · DOI · Paper page
- Piskulic, 2012, Negative symptoms in individuals at clinical high risk of psychosis, Psychiatry Res, 196, 220, 10.1016/j.psychres.2012.02.018 · DOI · Paper page
- Mason, 2004, Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’, Schizophr Res, 71, 227, 10.1016/j.schres.2004.04.006 · DOI · Paper page
- Demjaha, 2012, Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis, Schizophr Bull, 38, 351, 10.1093/schbul/sbq088 · DOI · Paper page
- Devoe, 2017, SU127. Negative symptoms in youth at clinical high risk of psychosis, Schizophr Bull, 43, S207, 10.1093/schbul/sbx024.123 · doi:10.1093/schbul/sbx024.123
- Bechdolf, 2005, Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls, Schizophr Res, 79, 137, 10.1016/j.schres.2005.06.008 · DOI
- Nelson, 2013, Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study, JAMA Psychiatry, 70, 793, 10.1001/jamapsychiatry.2013.1270 · DOI · Paper page
- Domínguez-Martínez, 2015, Subjective quality of life in At-Risk Mental State for psychosis patients: relationship with symptom severity and functional impairment, Early Interv Psychiatry, 9, 292, 10.1111/eip.12111 · DOI
- Wood, 2014, Negative symptoms in the at-risk mental state—association with transition to psychosis and functional outcome, Early Interv Psychiatry, 8, 23
- Fusar-Poli, 2015, Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials, Schizophr Bull, 41, 892, 10.1093/schbul/sbu170 · DOI · Paper page
- Carpenter, 2015, Diagnostic concepts in the context of clinical high risk/attenuated psychosis syndrome, Schizophr Bull, 41, 1001, 10.1093/schbul/sbv095 · DOI
- Kantrowitz, 2010, N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia, Brain Res Bull, 83, 108, 10.1016/j.brainresbull.2010.04.006 · DOI · Paper page
- Kantrowitz, 2016, “D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial”: correction, Lancet Psychiatry, 3, 602
- Amminger, 2010, Indicated prevention with long-chain omega-3 fatty acids in young people at ultra-high risk for psychosis: a randomized, placebo-controlled trial, Early Interv Psychiatry, 4, 7
- Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, b2700, 10.1136/bmj.b2700 · DOI · Paper page
- Stroup, 2000, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group, JAMA, 283, 2008, 10.1001/jama.283.15.2008 · DOI · Paper page
- Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ, 339:b2535
- Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
- Andreasen, 1989;17:173–180, Scale for the Assessment of Negative Symptoms (SANS), Br J Psychiatry Suppl, 10.1192/S0007125000291496 · DOI · Paper page
- Miller, 2003, Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability, Schizophr Bull, 29, 703, 10.1093/oxfordjournals.schbul.a007040 · DOI · Paper page
- Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions
- Boyle, 2013, Evaluation of the reliability and validity of GraphClick as a data extraction program, Comput Human Behav, 29, 1023, 10.1016/j.chb.2012.07.031 · DOI
- Peterson, 2011, The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses
- Woods, 2013, Glycine treatment of the risk syndrome for psychosis: report of two pilot studies, Eur Neuropsychopharmacol, 23, 931, 10.1016/j.euroneuro.2012.09.008 · DOI · Paper page
- DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
- Collaboration, 2011, Review manager (RevMan) [computer program]: Version
- Becker, 2000, Effect Size (ES)
- Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, J Clin Epidemiol, 50, 683, 10.1016/S0895-4356(97)00049-8 · DOI · Paper page
- Cates, 2014, Maintenance treatment for adults with chronic asthma, BMJ, 348:g3148
- Dias, 2013, Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials, Med Decis Making, 33, 641, 10.1177/0272989X12455847 · DOI · Paper page
- Song, 2003, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, 326, 472, 10.1136/bmj.326.7387.472 · DOI · Paper page
- Cohen, 1988, Statistical Power Analysis for the Behavioral Sciences, 20
- Woods, 2007, Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study, Br J Psychiatry Suppl, 51, s96, 10.1192/bjp.191.51.s96 · DOI
- Piskulic, 2012, Effects of cognitive remediation on cognition in young people at clinical high risk of psychosis, Schizophr Res, 136, S245, 10.1016/S0920-9964(12)70739-9 · doi:10.1016/s0920-9964(12)70739-9
- McFarlane, 2015, Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial, Schizophr Bull, 41, 30, 10.1093/schbul/sbu108 · DOI · Paper page
- Loewy, 2016, Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis, Schizophr Bull, 42, S118, 10.1093/schbul/sbw009 · DOI · Paper page
- Landa, 2016, Development of a group and family-based cognitive behavioural therapy program for youth at risk for psychosis, Early Interv Psychiatry, 10, 511, 10.1111/eip.12204 · DOI
- Hooker, 2014, A pilot study of cognitive training in clinical high risk for psychosis: initial evidence of cognitive benefit, Schizophr Res, 157, 314, 10.1016/j.schres.2014.05.034 · DOI · Paper page
- Choi, 2017, Pupillometer-based neurofeedback cognitive training to improve processing speed and social functioning in individuals at clinical high risk for psychosis, Psychiatr Rehabil J, 40, 33, 10.1037/prj0000217 · DOI · Paper page
- Cadenhead, 2017, 23. Omega-3 fatty acid versus placebo in a clinical high-risk sample from the North American Prodrome Longitudinal Studies (NAPLS) Consortium, Schizophr Bull, 43, S16, 10.1093/schbul/sbx021.042 · DOI
- Cannon, 2002, Antipsychotic drug treatment in the prodromal phase of schizophrenia, Am J Psychiatry, 159, 1230, 10.1176/appi.ajp.159.7.1230 · DOI
- Ising, 2016, Four-year follow-up of cognitive behavioral therapy in persons at ultra-high risk for developing psychosis: the Dutch Early Detection Intervention Evaluation (EDIE-NL) trial, Schizophr Bull, 42, 1243, 10.1093/schbul/sbw018 · DOI · Paper page
- Wessels, 2015, Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis, Psychiatr Prax, 42, 313
- Urben, 2012, A randomized controlled trial of the effectiveness of a computer-assisted cognitive remediation (CACR) program in adolescents with psychosis or at high risk of psychosis: short term and long term outcomes, Early Interv Psychiatry, 6, 41
- McGorry, 2013, Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome, J Clin Psychiatry, 74, 349, 10.4088/JCP.12m07785 · DOI · Paper page
- Berger, 2012, Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study, Curr Pharm Des, 18, 570, 10.2174/138161212799316163 · DOI · Paper page
- McGorry, 2017, Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial, JAMA Psychiatry, 74, 19, 10.1001/jamapsychiatry.2016.2902 · DOI · Paper page
- Kobayashi, 2009, Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state, J Clin Psychopharmacol, 29, 421, 10.1097/JCP.0b013e3181b2fe22 · DOI
- Liu, 2012, Aripiprazole for drug-naive or antipsychotic-short-exposure subjects at putatively prodromal or early state of psychosis: an open-label study, Early Interv Psychiatry, 6, 101
- Washida, 2013, Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia, Neuropsychiatr Dis Treat, 9, 861, 10.2147/NDT.S45697 · DOI
- Tsujino, 2013, Long-term efficacy and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open trial, Clin Psychopharmacol Neurosci, 11, 132, 10.9758/cpn.2013.11.3.132 · DOI
- Kumar, 2014, Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: an open-label clinical study, Ind Psychiatry J, 23, 27, 10.4103/0972-6748.144953 · DOI
- Danion, 1999, Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride, Am J Psychiatry, 156, 610, 10.1176/ajp.156.4.610 · DOI · Paper page
- Kim, 1980, Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia, Neurosci Lett, 20, 379, 10.1016/0304-3940(80)90178-0 · DOI · Paper page
- Heresco-Levy, 1999, Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia, Arch Gen Psychiatry, 56, 29, 10.1001/archpsyc.56.1.29 · DOI · Paper page
- Miyake, 2016, Effects of N-acetylcysteine on cognitive functions in subjects with an at-risk mental state: a case series, J Clin Psychopharmacol, 36, 87, 10.1097/JCP.0000000000000445 · DOI
- Sommer, 2016, Early interventions in risk groups for schizophrenia: what are we waiting for, NPJ Schizophr, 2, 16003, 10.1038/npjschz.2016.3 · DOI · Paper page
- Marder, 2011, Methodological issues in negative symptom trials, Schizophr Bull, 37, 250, 10.1093/schbul/sbq161 · DOI · Paper page
- Kirkpatrick, 2006, The NIMH-MATRICS consensus statement on negative symptoms, Schizophr Bull, 32, 214, 10.1093/schbul/sbj053 · DOI · Paper page
- Pelletier-Baldelli, Initial development and preliminary psychometric properties of the Prodromal Inventory of Negative Symptoms (PINS), Schizophr Res
- Corcoran, 2011, The relationship of social function to depressive and negative symptoms in individuals at clinical high risk for psychosis, Psychol Med, 41, 251, 10.1017/S0033291710000802 · DOI · Paper page
- Dong, 2015, Early intervention for psychosis with N-methyl-d-aspartate receptor modulators, Clin Psychopharmacol Neurosci, 13, 328, 10.9758/cpn.2015.13.3.328 · DOI
- Woods, 2014, NMDAR-based treatments for patients at clinical high risk for psychosis, Biol Psychiatry, 1, 11S
- Yung, 2012, Whither the attenuated psychosis syndrome, Schizophr Bull, 38, 1130, 10.1093/schbul/sbs108 · DOI · Paper page
Cited by
Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention
Fusar-Poli, P., Salazar de Pablo, G., Correll, C. U., Meyer-Lindenberg, A., Millan, M. J., Borgwardt, S., Galderisi, S., Bechdolf, A., Pfennig, A., Kessing, L. V., et al. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4779 · Cited by 476
Lack of evidence to favor specific preventive interventions in psychosis: a network meta‐analysis
Davies, C., Cipriani, A., Ioannidis, J. P. A., Radua, J., Stahl, D., Provenzani, U., McGuire, P., & Fusar‐Poli, P. (2018) · World Psychiatry · doi:10.1002/wps.20526 · Cited by 229
Firth, J., Teasdale, S. B., Allott, K., Siskind, D., Marx, W., Cotter, J., Veronese, N., Schuch, F., Smith, L., Solmi, M., et al. (2019) · World Psychiatry · doi:10.1002/wps.20672 · Cited by 214
Mei, C., van der Gaag, M., Nelson, B., Smit, F., Yuen, H. P., Berger, M., Krcmar, M., French, P., Amminger, G. P., Bechdolf, A., et al. (2021) · Clinical Psychology Review · doi:10.1016/j.cpr.2021.102005 · Cited by 143
Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence)
Fusar-Poli, P., Davies, C., Solmi, M., Brondino, N., De Micheli, A., Kotlicka-Antczak, M., Shin, J. I., & Radua, J. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00764 · Cited by 108
“Transition to psychosis Davies et al[30] 2018 Aggregate Network MetaAnalysis (RCTs) 16 (2035) 10/11 Lack of evidence to favour specific treatments Acceptability Davies et al[30] 2018 Aggregate Network MetaAnalysis (RCTs) 14 (1848) 10/11 Lack of evidence to favour specific treatments Severity of attenuated positive psy…”
BackgroundMethodInfluential
Metadata
- Authors
- Devoe, D. J., Peterson, A., & Addington, J.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-24
- Volume
- 44
- Issue
- 4
- Pages
- 807-823
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2765822046
- Cited by
- 80
- References
- 32
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- National Institute of Mental Health (RO1MH105178)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis. https://app.cochat.ai/papers/10.1093/schbul/sbx139
- The paper
- Devoe, D. J., Peterson, A., & Addington, J. (2018). Negative Symptom Interventions in Youth at Risk of Psychosis: A Systematic Review and Network Meta-analysis. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbx139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.